Agilent Technologies (A) Stock Price, Fundamentals & Analysis

What A does

Agilent Technologies (A) is a US stock in the Healthcare sector, focused on Diagnostics & Research. The company provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components, as well as liquid chromatography mass spectrometry systems, and is involved in genomics, contract development and manufacturing, pathology, companion diagnostics, and biomolecular analysis. The Agilent CrossLab segment provides services such as repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. A is part of the S&P 500.

Key numbers explained

• 165.32 USD is the latest price, representing the most recent trade on the market.
• The trailing P/E ratio of 32.6 shows how much investors pay per dollar of the last 12 months' earnings; a higher number often reflects growth expectations.
• The forward P/E ratio of 24.5 uses expected future earnings, which can make the stock look cheaper if earnings are projected to grow.
• 5.07 USD is the earnings per share (EPS) for the trailing 12 months, indicating the portion of profit attributable to each share.
• The dividend yield of 0.61% tells you the annual dividend as a percentage of the current price; the ex-dividend date is 6 Oct 2026.
• 20% of earnings are paid out as dividends, meaning the company retains most profit for reinvestment.
• 1.24 is the beta, meaning the stock tends to move about 24% more than the overall market in either direction.
• 108.35 – 168.94 is the 52-week price range, showing the lowest and highest prices over the past year.

Recent news

Recent headlines highlight long-term returns, noting that an investment of $1,000 a decade ago would be worth significantly more today. Other stories point to growth driven by China, replacement cycles, and lab automation, while additional coverage focuses on the label-free detection and array systems markets, comparing A with peers such as Revvity (RVTY) and others. The company also launched TapeStationDx systems for clinical NGS sample quality control.

What to watch

Investors typically monitor the diagnostics and research cycle, as demand for lab instruments and consumables can shift with funding, regulatory changes, and technological adoption. Competitive dynamics in label-free detection and life sciences tools, along with currency and geopolitical factors affecting markets like China, can also influence the stock. Earnings reports, such as the one scheduled for 25 Nov 2026, often drive short-term price moves.